Induction Therapy and Therapeutic Antibodies

Nikolova, Andriana P.; Patel, Jignesh

doi:10.1007/164_2021_570

Cited by 1 publication

(1 citation statement)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A systematic review indicated that antibody therapy was probably better than steroids in reversing acute cellular rejection and in preventing subsequent rejection, and also in preventing graft loss. T cell depleting antibodies are efficacious but associated with a much greater risk for adverse effects [ 8 , 9 ]. However, no information is available on rejection grades or clinical context; most studies were performed only with rejection in indication biopsies.…”

Section: Introductionmentioning

confidence: 99%

European Survey on Clinical Practice of Detecting and Treating T-Cell Mediated Kidney Transplant Rejection

Koshy,

Furian,

Nickerson

et al. 2024

Transpl Int

View full text Add to dashboard Cite

The KDIGO guideline for acute rejection treatment recommends use of corticosteroids and suggests using lymphocyte-depleting agents as second line treatment. Aim of the study was to determine the current practices of detection and treatment of TCMR of kidney allografts amongst European kidney transplant centres. An invitation was sent through ESOT/EKITA newsletters and through social media to transplant professionals in Europe for taking part in the survey. A total of 129 transplant professionals responded to the survey. There was equal representation of small and large sized transplant centres. The majority of centres treat borderline changes (BL) and TCMR (Grade IA-B, IIA-B) in indication biopsies and protocol biopsies with corticosteroids as first line treatment. Thymoglobulin is used mainly as second line treatment for TCMR Grade IA-B (80%) and TCMR IIA-B (85%). Treatment success is most often evaluated within one month of therapy. There were no differences observed between the large and small centres for the management of TCMR. This survey highlights the common practices and diversity in clinics for the management of TCMR in Europe. Testing new therapies for TCMR should be in comparison to the current standard of care in Europe. Better consensus on treatment success is crucial for robust study designs.

show abstract

Section: Introductionmentioning

confidence: 99%